Time to Treatment With Nivolumab or Pembrolizumab for Patients With Advanced Melanoma in Everyday Practice

Background The anti-programmed cell death one antibodies (Anti-PD-1 Ab) pembrolizumab or nivolumab are commonly prescribed to patients with advanced melanoma. The purpose of the current study is to identify baseline clinical characteristics associated with time to treatment initiation (TTI) of pembr...

Descripción completa

Detalles Bibliográficos
Autores principales: Ksienski, Doran, Truong, Pauline T, Croteau, Nicole S, Chan, Angela, Sonke, Eric, Patterson, Tiffany, Clarkson, Melissa, Lesperance, Mary
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Dermatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8702391/
https://www.ncbi.nlm.nih.gov/pubmed/34963849
http://dx.doi.org/10.7759/cureus.19835

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8702391/
https://www.ncbi.nlm.nih.gov/pubmed/34963849
http://dx.doi.org/10.7759/cureus.19835

Ejemplares similares